Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $4 | $2 | $4 |
| G&A Expenses | $1 | $1 | $1 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$2 | $0 | -$1 |
| Operating Expenses | $3 | $3 | $3 | $3 |
| Operating Income | -$3 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $1 | -$0 | $7 |
| Pre-Tax Income | -$3 | -$1 | -$3 | $4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$1 | -$3 | $4 |
| % Margin | – | – | – | – |
| EPS | -0.4 | -0.15 | -0.082 | 0.13 |
| % Growth | -166.7% | -82.3% | -163.3% | – |
| EPS Diluted | -0.4 | -0.15 | -0.082 | 0.13 |
| Weighted Avg Shares Out | 7 | 8 | 34 | 35 |
| Weighted Avg Shares Out Dil | 7 | 8 | 34 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$1 | -$3 | $4 |
| % Margin | – | – | – | – |